1100213-27-1

Basic information

• Product Name: 1H-Indazole-7-carboxaldehyde, 5-chloro-
• CAS NO: 1100213-27-1
• Molecular Formula: C8H5ClN2O
• Molecular Weight: 180.59100
• Mol File: 1100213-27-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Indazole-7-carboxaldehyde, 5-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-7-carboxaldehyde, 5-chloro-(1100213-27-1)
• EPA Substance Registry System: 1H-Indazole-7-carboxaldehyde, 5-chloro-(1100213-27-1)

Safety Data

• Hazardous Substances Data: 1100213-27-1(Hazardous Substances Data)

Usage

Structure

A derivative of indazole with a five-membered ring and two nitrogen atoms, with a 5-chloro substitution and an aldehyde group.

Usage

As a building block in the synthesis of various pharmaceuticals and organic compounds.

Versatility

The presence of the aldehyde group makes it a versatile intermediate for the preparation of other organic compounds.

Importance

Its structural characteristics and reactivity make it a valuable tool for chemical research and drug discovery.

Unique properties

The 5-chloro substitution on the indazole ring gives this compound unique chemical and biological properties.

Upstream product

• 875305-85-4 5-chloro-1H-indazole-7-carboxylic acid 
• 1260851-42-0 5-chloro-1H-indazole-7-carboxylic acid methyl ester 
• 20776-67-4 2-amino-5-chloro-3-methylbenzoic acid 
• 79101-83-0 2-amino-3-methyl-5-chlorobenzoic acid methyl ester 
• 875305-86-5 7-bromo-5-chloro-1H-indazole 
• 68-12-2 N,N-dimethyl-formamide 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE

Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR8; Z is formula (II); E is selected from optionally substituted alkyl, cycloalkyl, arylalkyl, cycloalkylalkyl, amino, alkoxy, cycloalkyloxy, and cycloalkylamino; R1 is selected from optionally substituted aryl and heteroaryl, R2 and R3 are independently selected from H, deutero, optionally substituted alkyl, haloalkyl, or R2 and R3, together with the carbon to which they are bound, combine to form a carbonyl; and R8 is selected from H, deutero, halo, hydroxyl, cyano, amino, alkyl, alkoxy, carboxy, alkoxycarbonyl, and aminocarbonyl, provided that E is not formula (III).

Substituted Heterocyclic Ethers and Their Use in CNS Disorders

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.